Core Viewpoint - Australia's CSL has entered into an exclusive licensing agreement with Eli Lilly and Co, allowing CSL to develop and commercialize clazakizumab, an antibody targeting specific medical conditions [1] Group 1: Licensing Agreement - The agreement grants CSL certain rights related to the development and commercialization of clazakizumab [1] - This partnership is expected to enhance CSL's portfolio in the biopharmaceutical sector [1] Group 2: Product Focus - Clazakizumab is an antibody aimed at treating specific medical conditions, indicating a focus on innovative therapies [1] - The collaboration with Eli Lilly highlights CSL's commitment to expanding its therapeutic offerings [1]

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance the global research and development of innovative drugs in oncology and immunology, marking a significant milestone in their long-term partnership [1] Group 1: Financial Aspects - Innovent Biologics received an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - Innovent Biologics retains the rights to all products in Greater China while Eli Lilly secures exclusive global development and commercialization rights outside this region [1] Group 2: Strategic Collaboration - This agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, further deepening their productive partnership [1] - The collaboration leverages Innovent's established antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept verification in China [1] - Eli Lilly will benefit from the global exclusive development and commercialization rights for the relevant projects outside Greater China [1]

消息面上，1月27日，英矽智能发布公告，英矽智能已与齐鲁制药集团及其附属公司上海齐鲁制药研究 中心，达成药物研发战略合作并签署相关协议。透过该合作，双方将依托英矽智能自有Pharma.AI解决 方案，针对特定靶点开展小分子抑制剂合作开发，关注心血管与代谢类疾病领域管理。 智通财经APP获悉，英矽智能(03696)涨近5%，截至发稿，涨4.5%，报59.2港元，成交额3446.85万港 元。 根据该协议的条款，英矽智能将利用自主搭建的Pharma.AI平台，关注用于代谢疾病领域的新颖小分子 药物设计与优化，齐鲁制药将负责后续开发与商业化工作。该协议总额超9.31亿港元，包含开发和销售 里程碑付款，以及单位数的后续净销售额分成。 ...

每经AI快讯，1月27日，英矽智能在港交所公告，公司已与齐鲁制药集团及其附属公司上海齐鲁制药研 究中心，达成药物研发战略合作并签署相关协议。透过该合作，双方将依托英矽智能自有Pharma.AI解 决方案，针对特定靶点开展小分子抑制剂合作开发，关注心血管与代谢类疾病领域管理。该协议总额超 过9.31亿港元，包含开发和销售里程碑付款，以及单位数的后续净销售额分成。 ...

Core Viewpoint - The collaboration between Insilico Medicine (03696) and Qilu Pharmaceutical Group aims to accelerate the development of innovative therapies for cardiovascular and metabolic diseases, with a total agreement value exceeding HKD 931 million [1] Group 1: Collaboration Details - Insilico Medicine has signed a strategic drug development cooperation agreement with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center [1] - The partnership will leverage Insilico's proprietary Pharma.AI solution to develop small molecule inhibitors targeting specific pathways in the management of cardiovascular and metabolic diseases [1] Group 2: Financial Aspects - The agreement includes milestone payments for development and sales, as well as a share of subsequent net sales based on unit numbers [1] - The total value of the agreement is over HKD 931 million, indicating significant financial commitment from both parties [1]

Core Viewpoint - The collaboration between 英矽智能 (InSilico Medicine) and 齐鲁制药集团 (Qilu Pharmaceutical Group) focuses on drug development in the cardiovascular and metabolic disease management sectors, leveraging InSilico's Pharma.AI platform for small molecule inhibitor development [1] Group 1: Collaboration Details - 英矽智能 has signed a strategic cooperation agreement with 齐鲁制药集团 and its subsidiary 上海齐鲁制药研究中心 (Shanghai Qilu Pharmaceutical Research Center) [1] - The partnership will utilize InSilico's proprietary Pharma.AI solutions to develop small molecule inhibitors targeting specific disease pathways [1] Group 2: Financial Aspects - The total value of the agreement exceeds 931 million HKD, which includes milestone payments for development and sales, as well as a share of subsequent net sales [1]

Core Viewpoint - The collaboration between Insilico Medicine and Qilu Pharmaceutical Group focuses on drug development in the cardiovascular and metabolic disease sectors, leveraging Insilico's Pharma.AI platform for small molecule inhibitor development [1] Group 1: Partnership Details - Insilico Medicine has signed a strategic cooperation agreement with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center [1] - The agreement involves the development of novel small molecule drugs targeting metabolic diseases, with Insilico utilizing its Pharma.AI platform [1] Group 2: Financial Aspects - The total value of the agreement exceeds HKD 931 million, which includes milestone payments for development and sales, as well as a share of subsequent net sales [1]

Core Insights - AstraZeneca has officially launched its Global R&D Beijing Strategic Center, marking its sixth global and second strategic R&D center in China, aimed at accelerating the translation of early drug research results into clinical development [1] Group 1: Strategic Initiatives - The new center is part of AstraZeneca's strategy to enhance drug development capabilities in China and globally [1] - AstraZeneca has announced collaborations with Cambridge University, Beijing Municipal Science and Technology Commission, Zhongguancun Science Park Management Committee, and Beijing Economic-Technological Development Area Management Committee [1] Group 2: Vision and Goals - AstraZeneca's UK Chairman, Shaun Grady, emphasized the goal of establishing a two-way connection between Beijing and Cambridge University, aiming for innovation that serves both local and global needs [1] - The initiative reflects AstraZeneca's view of China as a significant internal source of innovation while also pursuing external collaborations [1]

Core Viewpoint - ST HuLuWa (605199.SH) aims to enhance its core competitiveness and accelerate drug development by integrating R&D resources and sharing R&D risks through a technical cooperation agreement with related parties [1] Group 1: Company Actions - The company held a special meeting of independent directors and an extraordinary board meeting on October 17, 2025, to approve the proposal for signing a technical cooperation development contract [1] - The expected total R&D cost for the projects "Ondansetron Oral Soluble Film" and "Ibutamoren Right-Arm Injection Concentrate Solution" is budgeted to not exceed 11.25 million yuan [1] - Following board approval, the company will sign a technical cooperation development contract with Kang Lianxian to jointly develop the aforementioned projects [1]

Core Insights - Zealand Pharma has had an exciting year, highlighted by a significant partnership with Roche, which was established in March and has progressed rapidly towards Phase III for the petrelintide asset [3]. Company Overview - David Kendall has been with Zealand Pharma for 5 years and serves as the Chief Medical Officer, bringing prior experience from Eli Lilly and Amylin Pharmaceuticals [2]. Partnership Highlights - The partnership with Roche is a focal point for Zealand Pharma, with rapid advancements in their metabolism portfolio and the petrelintide asset [3].